Rather a paradox, on the day the SM got hit, and Morgan says...

Rather a paradox, on the day the SM got hit, and Morgan says 'take profits' , SRX goes up a small percentage, on good volume of 3/4m shares for $26m value.

One pays the piper and runs with the bulls at times.

I do like the upside valuation of GS One can live in hope I guess.

SMH


1:06pm: Sirtex has been the darling of the biotech space over the past 18 months or so as its share price has soared, but that surge has split broker opinion on the outlook.
After peaking recently at $36.23, it has corrected moderately. So far today it has ahead 0.6 per cent at $33.96.
Morgans CIMB reckons investors should take profits, telling them this morning Sirtex is in over-bought territory, after it breached its $35 share price target recently.
Goldman Sachs remains upbeat. After it slapped a $38 price target on the shares earlier in the year, it has now added Sirtex to its Australia Small & Mid Cap list, along with Cover-More, the travel insurer.
"While we assess the probability of clinical trial failure as low, the range of outcomes remains large and we note that Sirtex remains a higher-risk investment versus our coverage universe given that it is a single product company and faces a significant event catalyst," Goldman Sachs told clients. "That said, on current share prices, we view the risk/reward as favourable.
"Our bear/base/upside case valuation is $18/$43/$56."

Read more: http://www.smh.com.au/business/markets-live/markets-live-rio-banks-drag-shares-lower-20150304-3revc.html#ixzz3TPX3pIQU​